TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E-mutant metastatic colorectal cancer.

被引：0
|
作者：
Kotani, Daisuke
Kagawa, Yoshinori
Matsubara, Yuki
Bando, Hideaki
Harada, Kazuaki
Takahashi, Naoki
Mihara, Yoshiaki
Nakayama, Izuma
Izawa, Naoki
Kawakami, Takeshi
Masuishi, Toshiki
Hasegawa, Hiroko
Ohta, Takashi
Wakabayashi, Masashi
Yoshino, Takayuki
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[5] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[6] Saitama Canc Ctr, Saitama, Japan
[7] Saiatama Med Univ Int Med Ctr, Hidaka, Japan
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[9] St Marianna Univ Sch Med, Kawasaki, Kanagawa, Japan
[10] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Natl Hosp Org Osaka Natl Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[13] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
[14] Natl Canc Ctr Hosp East, Div Promot Drug & Diagnost Dev, Kashiwa, Chiba, Japan
[15] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS264
引用
收藏
页码：TPS264 / TPS264
页数：1
相关论文
共 50 条
  • [31] A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
    Baik, Christina
    Cheng, Michael L.
    Dietrich, Martin
    Gray, Jhanelle E.
    Karim, Nagla A.
    ADVANCES IN THERAPY, 2024, 41 (07) : 2586 - 2605
  • [32] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Shuosha Li
    Huabin Hu
    Dong Ding
    Youwen Zhu
    Jin Huang
    Advances in Therapy, 2021, 38 : 1650 - 1659
  • [33] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Li, Shuosha
    Hu, Huabin
    Ding, Dong
    Zhu, Youwen
    Huang, Jin
    ADVANCES IN THERAPY, 2021, 38 (03) : 1650 - 1659
  • [34] Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study
    Sakata, Hidenori
    Murase, Maki
    Kato, Takeshi
    Yamaguchi, Kensei
    Sugihara, Kenichi
    Suzuki, Shigenobu
    Yoshino, Takayuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 139 - 144
  • [35] Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
    Hidenori Sakata
    Maki Murase
    Takeshi Kato
    Kensei Yamaguchi
    Kenichi Sugihara
    Shigenobu Suzuki
    Takayuki Yoshino
    International Journal of Clinical Oncology, 2023, 28 : 139 - 144
  • [36] ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BIM), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Grothey, A.
    Yaeger, R.
    Paez, D.
    Tabernero, J.
    Taieb, J.
    Yoshino, T.
    Groc, M.
    Vedovato, J.
    Chetaille, E.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [37] BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Desai, Jayesh
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet
    Yoshino, Takayuki
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Loupakis, Fotios
    Hong, Yong Sang
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia Alfonso, Pilar
    Price, Timothy
    Strickland, Andrew
    Tebbutt, Niall
    Karapetis, Christos
    Chantrill, Lorraine
    Murphy, Felicity
    Sandor, Victor
    Christy-Bittel, Janna
    Anderson, Lisa
    Tabernero, Josep
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 99 - 99
  • [38] Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
    Wang, Xicheng
    Deng, Yanhong
    Zhang, Yanqiao
    Liu, Tianshu
    Yuan, Xianglin
    Yang, Jianwei
    Zhang, Tao
    Zang, Ai-min
    Liu, Yu
    Huang, Li
    Ye, Feng
    Zong, Hong
    Ba, Yi
    Klauck, Isabelle
    Vedovato, Jean-Claude
    Groc, Melanie
    Guo, Angela
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3559 - LBA3559
  • [39] Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.
    Udagawa, Shohei
    Osumi, Hiroki
    Ooki, Akira
    Wakatsuki, Takeru
    Fukuoka, Shota
    Yoshino, Koichiro
    Tamba, Mikako
    Ogura, Mariko
    Takahari, Daisuke
    Chin, Keisho
    Yamaguchi, Kensei
    Shinozaki, Eiji
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 142 - 142
  • [40] Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer
    Stammler, Romain
    Gallois, Claire
    Taieb, Julien
    Duong, Jean-Paul
    Karras, Alexandre
    Thervet, Eric
    Lazareth, Helene
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 60 - 62
12345